AmSurg shares receive ‘strong-buy’ rating — 6 notes

Zacks gave AmSurg shares a “strong-buy” rating, according to The Legacy.

Advertisement

Here are six notes:

1. AmSurg presently has a price target of $95.00.

2. AmSurg surpassed Zacks’ consensus estimate because of the company’s focus on organic growth and acquisition strategies.

3. AmSurg stock opened at $82.44 on Thursday, Aug. 6.

4. The company has a market cap of $3.93 billon and a P/E ration of 71.19.

5. AmSurg’s 50-day moving average price is $71.54 and its 200-day moving price is $64.80.

6. The company has a one-year low of $47.68 and a one-year high of $85.52.

More on surgery centers:
Barclay analysts raise SCA price target to $45 — 5 notes
Revere Health to break ground on new facility, surgery center
28 ASC joint ventures & acquisitions in 2015 so far

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Register to Attend Webinar

Is ambulatory care healthcare’s big margin engine? 4 leaders weigh in

Wednesday, July 29
1:00 PM - 2:00 PM CDT

Presenters: Joe Ganley, athenahealthJeffrey Flynn, CASC, Gramercy Surgery CenterBryan Tsao, Access Center, Loma Linda University HealthJason Zepeda, Northridge Hospital Medical Center, CommonSpirit HealthGreg DeConciliis, PA-C, CASC, Boston Out­Patient Surgical Suites

Advertisement

Next Up in ASC Transactions & Valuation Issues

Advertisement

Comments are closed.